Author

Laurent Peyrin-Biroulet

THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 DEMONSTRATES RAPID SYMPTOMATIC AND BIOMARKERS IMPROVEMENT IN ULCERATIVE COLITIS: RESULTS IN A PHASE 1B STUDY
THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 DEMONSTRATES RAPID SYMPTOMATIC AND BIOMARKERS IMPROVEMENT IN ULCERATIVE COLITIS: RESULTS IN A PHASE 1B STUDY

Laurent Peyrin-Biroulet  et al.

CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS
CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS

Laurent Peyrin-Biroulet  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Laurent Peyrin-Biroulet  et al.

CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB – A POST HOC ANALYSIS OF SELECTION
CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB – A POST HOC ANALYSIS OF SELECTION

Laurent Peyrin-Biroulet  et al.

ENDOSCOPIC AND HISTOLOGIC REMISSION AFTER 2 YEARS TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS
ENDOSCOPIC AND HISTOLOGIC REMISSION AFTER 2 YEARS TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS

Laurent Peyrin-Biroulet  et al.

RAPID SYMPTOMATIC RELIEF IS CORRELATED WITH EARLY ENDOSCOPIC RESPONSE TO THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS: RESULTS IN A PHASE 1B STUDY
RAPID SYMPTOMATIC RELIEF IS CORRELATED WITH EARLY ENDOSCOPIC RESPONSE TO THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS: RESULTS IN A PHASE 1B STUDY

Laurent Peyrin-Biroulet  et al.

IMPROVEMENT IN INFLAMMATORY BIOMARKER LEVELS THROUGH WEEK 12 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS PATIENTS TREATED WITH GUSELKUMAB: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
IMPROVEMENT IN INFLAMMATORY BIOMARKER LEVELS THROUGH WEEK 12 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS PATIENTS TREATED WITH GUSELKUMAB: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

Laurent Peyrin-Biroulet  et al.

IMPACT OF CONCOMITANT THIOPURINE ON THE EFFICACY AND SAFETY OF FILGOTINIB TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
IMPACT OF CONCOMITANT THIOPURINE ON THE EFFICACY AND SAFETY OF FILGOTINIB TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

Laurent Peyrin-Biroulet  et al.

TRAJECTORY MODELLING TO IDENTIFY DIFFERENT TYPES OF INDIVIDUAL RESPONSE TO THERAPY: A POST HOC ANALYSIS FROM THE SELECTION STUDY
TRAJECTORY MODELLING TO IDENTIFY DIFFERENT TYPES OF INDIVIDUAL RESPONSE TO THERAPY: A POST HOC ANALYSIS FROM THE SELECTION STUDY

Laurent Peyrin-Biroulet  et al.

ASSESSMENT OF HISTOLOGICAL REMISSION IN PATIENTS TREATED WITH FILGOTINIB BY DIFFERENT SCORES AND CONCORDANCE WITH ENDOSCOPIC AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES: POST HOC ANALYSIS FROM THE SELECTION STUDY
ASSESSMENT OF HISTOLOGICAL REMISSION IN PATIENTS TREATED WITH FILGOTINIB BY DIFFERENT SCORES AND CONCORDANCE WITH ENDOSCOPIC AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES: POST HOC ANALYSIS FROM THE SELECTION STUDY

Laurent Peyrin-Biroulet  et al.

EARLY DISEASE CLEARANCE WITH ETRASIMOD AND CORRELATION WITH WEEK 52 OUTCOMES AND BIOMARKERS: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC TRIALS
EARLY DISEASE CLEARANCE WITH ETRASIMOD AND CORRELATION WITH WEEK 52 OUTCOMES AND BIOMARKERS: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC TRIALS

Laurent Peyrin-Biroulet  et al.

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1

Laurent Peyrin-Biroulet  et al.

THE EFFICACY OF INDUCTION TREATMENT WITH GUSELKUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY RESULTS AT WEEK 12 BY PRIOR ADVANCED THERAPY HISTORY
THE EFFICACY OF INDUCTION TREATMENT WITH GUSELKUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY RESULTS AT WEEK 12 BY PRIOR ADVANCED THERAPY HISTORY

Laurent Peyrin-Biroulet  et al.

PREDICTORS OF RESPONSE TO FILGOTINIB IN ULCERATIVE COLITIS: POST HOC ANALYSIS FROM THE SELECTION STUDY
PREDICTORS OF RESPONSE TO FILGOTINIB IN ULCERATIVE COLITIS: POST HOC ANALYSIS FROM THE SELECTION STUDY

Laurent Peyrin-Biroulet  et al.

The real-world experience: Navigating the ocean of JAKi evidence to help improve outcomes for patients with UC (Pfizer Inc.) (Complete Session)
The real-world experience: Navigating the ocean of JAKi evidence to help improve outcomes for patients with UC (Pfizer Inc.) (Complete Session)

Laurent Peyrin-Biroulet  et al.

Revolutionizing the treatment landscape in Crohn’s disease: How IL-23 and JAK inhibitors are changing the rhythm (AbbVie) (Complete Session)
Revolutionizing the treatment landscape in Crohn’s disease: How IL-23 and JAK inhibitors are changing the rhythm (AbbVie) (Complete Session)

Laurent Peyrin-Biroulet  et al.

IMPACT OF PRIOR BIOLOGIC/JANUS KINASE INHIBITOR THERAPY ON THE EFFICACY OF ETRASIMOD: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
IMPACT OF PRIOR BIOLOGIC/JANUS KINASE INHIBITOR THERAPY ON THE EFFICACY OF ETRASIMOD: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Laurent Peyrin-Biroulet  et al.

PHYSICIAN PREFERENCES FOR BIOLOGICS FOR THE TREATMENT OF CROHN'S DISEASE AND ULCERATIVE COLITIS IN FRANCE, GERMANY AND THE UNITED KINGDOM
PHYSICIAN PREFERENCES FOR BIOLOGICS FOR THE TREATMENT OF CROHN'S DISEASE AND ULCERATIVE COLITIS IN FRANCE, GERMANY AND THE UNITED KINGDOM

Laurent Peyrin-Biroulet  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Laurent Peyrin-Biroulet  et al.

ENDOSCOPIC AND HISTOLOGIC IMPROVEMENTS WITH PRA023 IN ARTEMIS-UC, A PHASE 2 PLACEBO-CONTROLLED STUDY ON MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
ENDOSCOPIC AND HISTOLOGIC IMPROVEMENTS WITH PRA023 IN ARTEMIS-UC, A PHASE 2 PLACEBO-CONTROLLED STUDY ON MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Laurent Peyrin-Biroulet  et al.

Item 41 - 60 / 115
1 2
3
4 5 6